2023-10-18
同时，通过本次合作，该MNC将迅速推进无血清细胞培养基的新原料发现与验证，及培养基工艺的深度优化，将大幅提高生物制品研发和培养基供应效率，提升无血清细胞培养基的未来发展。
Great Bay Bio’s AlfaCell Delivers Average Titer Above 6.9 g/L Across Client Projects, with RCB Completed in Just 1.5 Months
2026-03-27
Great Bay Bio Recognized in the Deloitte Greater Bay Area Technology Fast 40 & Rising Star Program, Receiving Further Authoritative Recognition for AI-Enabled Bioprocess Innovation
2026-03-26
Great Bay Bio’s CHO-K1 Catalog Medium AlfaMedX- K1 (Growth Factor–Free) Achieves FDA DMF Filing
2026-03-09
